Metabolic tumor volume predicts overall survival in patients with primary pulmonary lymphoepithelioma‑like carcinoma
- Chun‑Yu Lin
- Yu‑Chuan Chang
- I‑Ting Wang
- Meng‑Heng Hsieh
- Chih‑Wei Wang
- Shu‑Min Lin
- Ching‑Yang Wu
- Yueh‑Fu Fang
Affiliations: Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 33305, Taiwan, R.O.C., Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan, R.O.C., Department of Pulmonary and Critical Care, Mackay Memorial Hospital, Taipei 10491, Taiwan, R.O.C., Department of Pathology, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan 33305, Taiwan, R.O.C., Department of Surgery, Division of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan 33305, Taiwan, R.O.C.
- Published online on: October 2, 2019 https://doi.org/10.3892/ol.2019.10954
Copyright: © Lin
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Pretreatment tumor metabolic burden, measured using fluorine‑18 fluorodeoxyglucose positron emission tomography/computerized tomography (18F‑FDG PET/CT), has been demonstrated to predict outcomes in various types of malignancies. Additionally, Epstein‑Barr virus (EBV) serum titer is associated with stages of pulmonary lymphoepithelioma‑like carcinoma (LELC). The present study aimed to investigate the prognostic value of the functional parameters of 18F‑FDG PET/CT in pulmonary LELC and their association with serum EBV DNA. The present retrospective study analyzed data from 71 patients with pulmonary LELC; among these, 32 patients with pulmonary LELC underwent pretreatment 18F‑FDG PET/CT staging between January 2008 and December 2016. EBV viral load and functional parameters of 18F‑FDG PET/CT were used for survival analysis. Multivariate analysis identified tumor stage IV as a significant predictor of poor progression‑free survival [hazard ratio (HR), 4.85; P=0.049], whereas elevated total metabolic tumor volume (MTV ≥72.6 ml) independently predicted worse overall survival (OS; HR, 12.59; P=0.024). Pretreatment serum EBV DNA titer was significantly positively associated with total MTV (P=0.0337) and total lesion glycolysis (TLG; P=0.0093), but could not predict outcomes. Total MTV was an independent predictor of OS, and may guide clinical management for pulmonary LELC.